Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer. Shares of the struggling vaccine developer Novavax (NVAX 47.63%) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant that wants to market Novavax's COVID-19 and influenza vaccines. The recent Novavax stock rally continued after the weekend and investors are right to wonder if it has more fuel to climb higher ...